Literature DB >> 12610147

Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.

Simone Giannecchini1, Armida Di Fenza, Anna Maria D'Ursi, Donatella Matteucci, Paolo Rovero, Mauro Bendinelli.   

Abstract

Feline immunodeficiency virus (FIV) provides a valuable animal model by which criteria for lentivirus control strategies can be tested. Previous studies have shown that a 20-mer synthetic peptide of the membrane-proximal ectodomain of FIV transmembrane glycoprotein, designated peptide 59, potently inhibited the growth of tissue culture-adapted FIV in feline fibroblastoid CrFK cells. In the present report we describe the potential of this peptide to inhibit the replication of primary FIV isolates in lymphoid cells. Because antiviral activity of peptide 59 was found to map to a short segment containing three conserved Trp residues, further analyses focused on a derivative of eight amino acids ((770)W-I(777)), designated C8. Peptide C8 activity was found to be dependent on conservation of the Trp motif, to be removed from solution by FIV absorbed onto substrate cells, and to be blocked by a peptide derived from the N-terminal portion of FIV transmembrane glycoprotein. Structural studies showed that peptide C8 possesses a conformational propensity highly uncommon for peptides of its size, which may account for its considerable antiviral potency in spite of small size.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610147      PMCID: PMC149492          DOI: 10.1128/jvi.77.6.3724-3733.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1.

Authors:  J H Elder; G A Dean; E A Hoover; J A Hoxie; M H Malim; L Mathes; J C Neil; T W North; E Sparger; M B Tompkins; W A Tompkins; J Yamamoto; N Yuhki; N C Pedersen; R H Miller
Journal:  AIDS Res Hum Retroviruses       Date:  1998-06-10       Impact factor: 2.205

3.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.

Authors:  D C Chan; C T Chutkowski; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Neutralization sensitivity and accessibility of continuous B cell epitopes of the feline immunodeficiency virus envelope.

Authors:  J Richardson; I Fossati; A Moraillon; S Castelot; P Sonigo; G Pancino
Journal:  J Gen Virol       Date:  1996-04       Impact factor: 3.891

5.  Binding of recombinant feline immunodeficiency virus surface glycoprotein to feline cells: role of CXCR4, cell-surface heparans, and an unidentified non-CXCR4 receptor.

Authors:  A de Parseval; J H Elder
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

Authors:  L T Rimsky; D C Shugars; T J Matthews
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism.

Authors:  J K Judice; J Y Tom; W Huang; T Wrin; J Vennari; C J Petropoulos; R S McDowell
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines.

Authors:  J K Yamamoto; C D Ackley; H Zochlinski; H Louie; E Pembroke; M Torten; H Hansen; R Munn; T Okuda
Journal:  Intervirology       Date:  1991       Impact factor: 1.763

9.  Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change.

Authors:  M A Rigby; E C Holmes; M Pistello; A Mackay; A J Brown; J C Neil
Journal:  J Gen Virol       Date:  1993-03       Impact factor: 3.891

10.  Nucleotide sequence and genomic organization of feline immunodeficiency virus.

Authors:  R L Talbott; E E Sparger; K M Lovelace; W M Fitch; N C Pedersen; P A Luciw; J H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

View more
  15 in total

1.  Receptor-triggered but alkylation-arrested env of murine leukemia virus reveals the transmembrane subunit in a prehairpin conformation.

Authors:  Michael Wallin; Maria Ekström; Henrik Garoff
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Effects of HIV-1 gp41-Derived Virucidal Peptides on Virus-like Lipid Membranes.

Authors:  Pablo Carravilla; Antonio Cruz; Itziar Martin-Ugarte; Itziar R Oar-Arteta; Johanna Torralba; Beatriz Apellaniz; Jesús Pérez-Gil; José Requejo-Isidro; Nerea Huarte; José L Nieva
Journal:  Biophys J       Date:  2017-08-07       Impact factor: 4.033

3.  Conformational properties of peptides corresponding to the ebolavirus GP2 membrane-proximal external region in the presence of micelle-forming surfactants and lipids.

Authors:  Lauren K Regula; Richard Harris; Fang Wang; Chelsea D Higgins; Jayne F Koellhoffer; Yue Zhao; Kartik Chandran; Jianmin Gao; Mark E Girvin; Jonathan R Lai
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

4.  Structural characterization of the feline-immunodeficiency-virus envelope glycoprotein 36 ectodomain for the development of new antivirals.

Authors:  Florestan Desmaris; David Lemaire; Sylvie Ricard-Blum; Benoît Chatrenet; Eric Forest
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

5.  Antibodies generated in cats by a lipopeptide reproducing the membrane-proximal external region of the feline immunodeficiency virus transmembrane enhance virus infectivity.

Authors:  Simone Giannecchini; Anna Maria D'Ursi; Cinzia Esposito; Mario Scrima; Elisa Zabogli; Giulia Freer; Paolo Rovero; Mauro Bendinelli
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

Review 6.  Feline immunodeficiency virus (FIV) neutralization: a review.

Authors:  Margaret J Hosie; Daniela Pajek; Ayman Samman; Brian J Willett
Journal:  Viruses       Date:  2011-10-13       Impact factor: 5.048

Review 7.  Pharmacological inhibition of feline immunodeficiency virus (FIV).

Authors:  Hakimeh Mohammadi; Dorothee Bienzle
Journal:  Viruses       Date:  2012-04-27       Impact factor: 5.048

8.  Peptides derived from HIV-1, HIV-2, Ebola virus, SARS coronavirus and coronavirus 229E exhibit high affinity binding to the formyl peptide receptor.

Authors:  John S Mills
Journal:  Biochim Biophys Acta       Date:  2006-06-06

9.  Interaction of short modified peptides deriving from glycoprotein gp36 of feline immunodeficiency virus with phospholipid membranes.

Authors:  Gerardino D'Errico; Giuseppe Vitiello; Anna Maria D'Ursi; Derek Marsh
Journal:  Eur Biophys J       Date:  2009-05-05       Impact factor: 1.733

10.  Differential activation of polymorphisms of the formyl peptide receptor by formyl peptides.

Authors:  John S Mills
Journal:  Biochim Biophys Acta       Date:  2007-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.